Patents Represented by Attorney Jeffrey H. Tidwell

Find this attorney in the Justia Lawyer Directory

  • HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
    Patent number: 7169932
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: January 30, 2007
    Assignee: Pfizer Inc.
    Inventors: David John Kucera, Robert William Scott
  • Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
    Patent number: 7151105
    Abstract: The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: December 19, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Javier Gonzalez, Tanya Michelle Jewell, Hui Li, Angelica Linton, John Howard Tatlock
  • Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
    Patent number: 7148226
    Abstract: The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
    Type: Grant
    Filed: November 19, 2003
    Date of Patent: December 12, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Allen Borchardt, Javier Gonzalez, Hui Li, Maria Angelica Linton, John Howard Tatlock
  • HIV integrase inhibitors, pharmaceutical compositions and methods for their use
    Patent number: 7138408
    Abstract: Beta-carboline hydroxamic acid compounds represented by formula (I) are described. The beta-carboline hydroxamic acid compounds and compositions containing those compounds may be used to inhibit or modulate the activity of HIV integrase enzyme and to treat HIV integrase-mediated diseases and conditions.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: November 21, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Atsuo Kuki, Xinqiang Li, Michael Bruno Plewe, Hai Wang, Junhu Zhang
  • HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use
    Patent number: 7135482
    Abstract: Bicyclic hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: November 14, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Qiyue Hu, Ted William Johnson, Atsuo Kuki, Michael Bruno Plewe, Dawn Marie Nowlin, Hai Wang, Junhu Zhang
  • Inhibitors of hepatitis C virus RNA-dependent RNA polymerase
    Patent number: 7115658
    Abstract: Compounds of formula I are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus
    Type: Grant
    Filed: May 9, 2003
    Date of Patent: October 3, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Allen J. Borchardt, Peter Scott Dragovich, Javier Gonzalez, Tanya Michelle Jewell, Hui Li, Maria Angelica Linton, John Howard Tatlock, Ru Zhou, Thomas Jay Prins, Melwyn A. Abreo
  • HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
    Patent number: 7094909
    Abstract: The present invention concerns processes for preparing compounds of formula (I-H), or a prodrug, pharmaceutically active metabolite, or pharmaceutically active salt or solvate thereof, which are useful as inhibitors of the HIV protease enzyme.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: August 22, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: David John Kucera, Robert William Scott
  • Process to produce enantiomerically enriched alcohols and amines
    Patent number: 7045646
    Abstract: This invention describes a convenient method for the preparation and use of a ruthenium catalyst for a chiral reduction of ketones and imines.
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: May 16, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Steven P. Tanis, Bruce Evans
  • Inhibitors of HCV NS5B polymerase
    Patent number: 7041690
    Abstract: The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: May 9, 2006
    Assignee: Pharmacia & Upjohn Company, LLC
    Inventors: Barry Craig Finzel, Hua Gao, Meredith L. Greene, Rebecca J. Gross, Richard Allen Nugent, Jeffrey A. Pfefferkorn
  • Inhibitors of HCV NS5B polymerase
    Patent number: 7026339
    Abstract: The present invention relates to compounds, process for their synthesis, compositions and methods for the treatment and prevention of hepatitis C virus (HCV) infection. In particular, the present invention provides novel compounds, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment or prevention of HCV infection. The present invention also provides processes and intermediates for the synthesis of these compounds.
    Type: Grant
    Filed: November 3, 2004
    Date of Patent: April 11, 2006
    Inventors: Fan Yang, Bo Zhang, Nancy Anne Wicnienski, Jeffrey Allen Pfefferkorn, Meredith L. Greene, Ke Chen, Richard A. Nugent, Matthew Todd Reding, Robert Charles Kelly, Mark A. Mitchell, Lee A. Funk, Richard Frederick Heier, III, Rebecca Merry Anderson
  • HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use
    Patent number: 7001912
    Abstract: Beta-carboline hydroxamic acid compounds represented by formula (I) are described. The beta-carboline hydroxamic acid compounds and compositions containing those compounds may be used to inhibit or modulate the activity of HIV integrase enzyme and to treat HIV integrase-mediated diseases and conditions.
    Type: Grant
    Filed: January 26, 2004
    Date of Patent: February 21, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Atsuo Kuki, Xinqiang Li, Michael Bruno Plewe, Hai Wang, Junhu Zhang
  • Inhibitors of HCV NS5B polymerase
    Patent number: 6930106
    Abstract: The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: August 16, 2005
    Assignee: Pharmacia & UpJohn Company
    Inventors: Barry Craig Finzel, Lee A. Funk, Robert Charles Kelly, Matthew T. Reding, Nancy Anne Wicnienski